FLB Stock Overview
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.34 |
| 52 Week High | US$2.80 |
| 52 Week Low | US$1.33 |
| Beta | 1.64 |
| 1 Month Change | -5.65% |
| 3 Month Change | 7.34% |
| 1 Year Change | 51.95% |
| 3 Year Change | -41.51% |
| 5 Year Change | -81.34% |
| Change since IPO | -79.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| FLB | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -8.6% | -9.9% | -2.0% |
| 1Y | 51.9% | -14.9% | -0.3% |
Return vs Industry: FLB exceeded the German Life Sciences industry which returned -14.9% over the past year.
Return vs Market: FLB exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| FLB volatility | |
|---|---|
| FLB Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FLB has not had significant price volatility in the past 3 months.
Volatility Over Time: FLB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 537 | Michael Egholm | www.standardbio.com |
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Standard BioTools Inc. Fundamentals Summary
| FLB fundamental statistics | |
|---|---|
| Market cap | €911.61m |
| Earnings (TTM) | -€70.06m |
| Revenue (TTM) | €99.79m |
9.1x
P/S Ratio-13.0x
P/E RatioIs FLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLB income statement (TTM) | |
|---|---|
| Revenue | US$106.34m |
| Cost of Revenue | US$55.89m |
| Gross Profit | US$50.45m |
| Other Expenses | US$125.11m |
| Earnings | -US$74.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 47.44% |
| Net Profit Margin | -70.21% |
| Debt/Equity Ratio | 38.9% |
How did FLB perform over the long term?
See historical performance and comparison